Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour By Ogkologos - March 18, 2026 219 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MANEUVER study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR New on NCI’s Websites for June 2023 June 29, 2023 Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with... November 5, 2025 Targeting FGFR1 in Patients with Tumour-Induced Osteomalacia September 16, 2020 Newly Discovered ‘Don’t Eat Me’ Signal May be a Target for... August 20, 2019 Load more HOT NEWS Could food improve cancer treatment? – That Cancer Conversation NHL Team Surprises Big Fan Who Spent Breast Cancer Treatment Performing... Avelumab Ineffective in Patients with MSS Endometrial Cancer Carrying TP53 Mutation Drug Combination May Have Potential for Cancers with TP53 Mutations
